Laboratory Managed Serivce · UK public procurement notice

CPV: Biomedical equipment · Installation services of laboratory equipment

Procedure method

Negotiated without publication of a contract notice

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Competitive procedure

GPA / WTO covered

Unspecified in notice

Recurring procurement

Unspecified in notice

First published

9 Dec 2022, 16:36 GMT

Last source update

9 Dec 2022, 16:36 GMT

FTS notice number

2022/S 000-034983

Classification (CPV)

Biomedical equipmentInstallation services of laboratory equipment

Delivery area

West Midlands (UKG)

Official registry OCID

ocds-h6vhtk-038c67 Find a Tender

Why no open competition

The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive; The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons

Published justification

University Hospitals Birmingham NHS Trust (UHB) intends to enter into a new contract with Abbott Laboratories Limited.

The main benefit of entering into this contract revolves around the stability of application platforms while service consolidation takes place over the networks. As stated in the NHSE state of the nation document;

“Consolidating pathology services allows for most consistent, clinically appropriate turnaround times ensuring the right test is available at the right time… consolidation can ensure an appropriate critical mass to support specialist diagnostics, so that patients have equal access to key tests and services are sustainable”

As the capacity for change in the system is currently limited by post-Covid recovery plans, increased Emergency Department activity and other important projects for future productivity and performance (i.e. the current implantation of a new LIMS) a change of supplier will endanger the successful delivery of all of these important projects.

Aligned to this a change of major analytical platform – however well planned – will always likely result is a reduction in productivity and consequently the restoration and recovery plan will be severely affected as will current ED turnaround times. It is assessed that the patients of Birmingham and Solihull will be put at a significant disadvantage if a fundamental piece of the diagnostic process undergoes change at this moment in time.

Future projects will be enabled and better served by not embarking on a period of change, particularly with reference to a wider BSOL ICS consolidation – including Birmingham Women’s and Children’s Hospital. In addition, with the implementation of the LIMS across BSOL, in future we will have a digital environment which is standardised and working in all providers of laboratory services in Birmingham and Solihull, reducing the risks of making an analytical transition for the trusts and the suppliers.

• Abbott Laboratories LimitedAwarded supplier00329102 Abbott House Vanwall Business Park, Vanwall Road,, Maidenhead, South East, SL6 4XE

No document links were published on the notice.